Interim Report January – September 2019
Erik Kinnman, born 1958, is a seasoned life science executive with broad experience and understanding from the industry across a variety of businesses and functions. He has held a number of senior leadership positions in biopharmaceutical companies such as AstraZeneca and Sobi. His expertise and experience includes clinical development, business strategy, business development, and investor relations. Erik Kinnman also has experience from the financial sector. In addition, he holds an Executive MBA from the Stockholm School of Economics and has comprehensive scientific qualifications from the Karolinska Institutet, which has rendered him a Ph.D. and an Associate Professor. Moreover, Erik Kinnman is an M.D., board certified in Neurology and Pain Management. Erik is Chairman of the Board of Directors in Kinnman Solutions AB. Employed since 2016.
No of shares: 400 298
Catharina Jz Johansson, born 1967, possesses experience from work on medtech growth enterprises with multinational operations. Catharina Johansson holds a M.Sc. in Business and Economics. Her previous experience includes serving as interim CFO for medical device company Cellavision, which is listed on Nasdaq Stockholm, and Accounting Manager for Bong and Alfa Laval Europe. Employed since 2013.
No of shares: 60 000
Eskil Elmér, born 1970, is associate professor of experimental neurology at Lund University (Sweden) and group leader of the Mitochondrial Medicine lab at the department of Clinical Neurophysiology. Dr Elmér is patentee and co-founder of both Maas Biolab, LLC and NeuroVive Pharmaceutical AB, and CSO of NeuroVive, with overall charge of the company's pre-clinical research. In addition, Eskil Elmér is a practising physician in the department of clinical neurophysiology at Skåne University Hospital in Lund, Sweden. Employed since 2000.
No of shares: 577 487 Privately owned (including family) and 17.09% of Maas Biolab, LLC which owns 4.2% of NeuroVive.
Magnus Hansson, born 1976, has extensive experience in the area of Mitochondrial Medicine. He has previously been serving as a Senior Scientist in NeuroVive since 2008 and as a consultant physician and associate professor in medical imaging and physiology at Skåne University Hospital, Sweden. Dr Hansson has overall charge of the company’s pre-clinical and clinical development programs. He holds a PhD in Experimental brain research from Lund University, Sweden and has authored more than 30 scientific publications and 10 patent applications. Employed since 2008.
No of shares: 414 339 (including family)
Mark Farmery, born 1969, is a senior executive with more than 15 years’ experience in biopharma business development from Karolinska Institutet Innovations AB, AstraZeneca and Karo Bio AB. He has also managed research teams and led specific projects in the fields of Alzheimer’s disease modification and protein modification and misfolding at Karolinska Institutet and the Universities of Gothenburg and Manchester. Dr Farmery received his BSc in Biomedical Sciences (Microbiology) from the University of Bradford and his PhD in Biochemistry and Molecular Microbiology from the University of Leeds. Employed since 2017.
No of shares: 13 225